Recreational marijuana proposal certified for Alaska ballot By Steve Quinn Reuters February 27, 2014     Pivotal Point Is Seen as More States Consider Legalizing Marijuana By Rick Lyman February 26, 2014

 

http://io9.com/a-short-animation-about-the-worlds-first-intentional-l-1529827739

 

 

A short animation about the world's first intentional LSD trip io9 On April 19, 1943, chemist Albert Hofmann intentionally ingested LSD, and felt the drug's hallucinogenic effects while riding his bicycle home. Flag as irrelevant

 

 

 

 

Ayahuasca Is the New Juice Cleanse New York Magazine Like yoga and juice-fasting before it, ayahuasca has gone from being an ancient spiritual practice to a hippie hobby to an expensive form of ... Flag as irrelevant

 

 

 

 

Can psilocybin mushrooms cure cocaine addiction? UAB study aims to find out. The Birmingham News - al.com (blog) Starting later this year, a researcher at the University of Alabama at Birmingham said he hopes to begin giving psilocybin obtained from hallucinogenic ...

 

 

 

 

European initiative for legalisation of marihuana kicks off: Medical Marijuana Bulgaria Focus News The European Citizens' Initiative “Weed Like to Talk” aims at making the EU adopt a common policy on the control and regulation of cannabis ... Flag as irrelevant

 

 

 

http://www.eurekalert.org/pub_releases/2014-02/sp-hp021814.php

 

Hudson, A. L., Lalies, M. D., Baker, G. B., Wells, K., & Aitchison, K. J. (2014). Ecstasy, legal highs and designer drug use: A Canadian perspective. Drug Science, Policy and Law, 1, 1-9.

 

 

 

 

 

The judges fight back……

Minimum sentence for drug trafficking struck down by B.C. judge Provincial court Judge Joseph Galati says law is 'cruel and unusual punishment' contrary to charter CBC News February 19, 2014

 

 

See attached invitation to attend the book launch Killer Weed.

Cheers,

Mark Haden

> http://www.ladybud.com/2014/02/10/the-war-on-weed-is-a-war-on-the-elde
> rly/
>

The New York Times
Wednesday, February 12, 2014

We Need Proof on Marijuana

By ORRIN DEVINSKY and DANIEL FRIEDMAN

MANY people have heard the story of Charlotte Figi, a young girl from
Colorado with severe epilepsy. After her parents began giving her a
marijuana strain rich in cannabidiol (CBD), the major nonpsychoactive
ingredient in marijuana, Charlotte reportedly went from having hundreds of
seizures per week to only two or three per month. Previously, her illness,
Dravet Syndrome, was a daily torture despite multiple high doses of powerful
anti-seizure drugs.

As news of Charlotte's story moved from the Internet to a CNN story by Dr.
Sanjay Gupta to Facebook pages, some families of children with similar
disorders moved to Colorado, which recently legalized marijuana, to reap
what they believe are the benefits of the drug.

Dozens of other anecdotes of miraculous responses to marijuana treatments in
children with severe epilepsy are rife on Facebook and other social media,
and these reports have aroused outsize hopes and urgent demands. Based on
such reports, patients and parents are finding official and backdoor ways to
give marijuana to their children.

But scientific studies have yet to bear out the hopes of these desperate
families. The truth is we lack evidence not only for the efficacy of
marijuana, but also for its safety. This concern is especially relevant in
children, for whom there is good evidence that marijuana use can increase
the risk of serious psychiatric disorders and long-term cognitive problems.

The recent wave of state legislatures considering and often approving
medical marijuana raises significant concerns. By allowing marijuana therapy
for patients with diseases such as difficult-to-control epilepsy, are state
legislatures endorsing the medical benefits and safety of a broad range of
marijuana species and strains before they have been carefully tested and
vetted? Marijuana contains around 80 cannabinoids (THC is the major
psychoactive cannabinoid, largely responsible for the high) and more than
400 other compounds. The chemical composition of two genetically identical
plants can vary based on growing conditions, soil content, parasites and
many other factors.

While the language of the legislation may be cautious, there is an implied
endorsement of medical benefit for marijuana when a legislature passes a
bill and a governor signs it into law, and the tremendous gaps in our
knowledge are not effectively conveyed to the public.

Where is the data showing that marijuana is effective for epilepsy?
Although parents may report improvements in their children, it is important
to remember that the placebo response is powerful, and the placebo response
is greater in pediatric than adult studies.

Before more children are exposed to potential risks, before more desperate
families uproot themselves and spend their life savings on unproven miracle
marijuana cures, we need objective data from randomized placebo-controlled
trials.
Recent Comments
Brian
9 hours ago

Why do we need "proof" on marijuana when we don't have it on some of the
most widely used drugs in America. Check out the peer reviewed...
Marc Wagner
9 hours ago

Fine approve it for consumption but not for SMOKING. Does anyone think it is
the nicotine that kills smokers? No, it is the combustion...
Jane
9 hours ago

Years ago, at that bastion of conservativism UC Berkeley, we got a lecture
in a toxicology class by a clinical researcher who was very...

See All Comments

Based on studies showing that CBD can prevent seizures in animals and safety
data from patients treated with a drug containing CBD and THC in Europe for
multiple sclerosis spasms, we and other academic epilepsy centers are
planning a controlled trial with pure CBD. As an initial step, we have
approval from the Food and Drug Administration, the Drug Enforcement
Administration and the Bureau of Narcotic Enforcement to treat children with
CBD derived from marijuana plants in order to understand its safety and
tolerability and potential drug interactions.
This information will help us plan the placebo-controlled trials that we
hope will begin in 2014 and will be completed within two years. There is no
reason such studies cannot be done with other products derived from
marijuana, such as the oil with high CBD and low THC sold in Colorado that
was used by Charlotte Figi.

Paradoxically, however, as state governments increasingly make "medical"
marijuana available to parents to give to their children, the federal
government continues to label the nonpsychoactive CBD - as well as THC - as
Schedule 1 drugs. Such drugs are said to have "no currently accepted medical
use in the United States, a lack of accepted safety for use under medical
supervision, and a high potential for abuse." This designation hamstrings
doctors from performing controlled studies. While it is possible to study
Schedule 1 drugs in a controlled laboratory setting, it is extremely
difficult to study these substances in patients. For our study, we keep the
CBD in a 1,200-pound safe in a locked room, in a building with an alarm
system.

To foster research, we need to change compounds derived from marijuana from
Schedule 1 to a less restrictive category. It is troubling that while few
barriers exist for parents to give their children marijuana in Colorado,
there are significant federal roadblocks preventing doctors from studying it
in a rigorous scientific manner.

When patients have not been able to get successful medical treatment, and
they live in a state where the law allows medical marijuana for children -
we are not suggesting they smoke the drug - compassionate use is reasonable.

But for the long-term health of Charlotte and other patients like her, we
urgently need valid data.

----
Orrin Devinsky and Daniel Friedman are physicians at the NYU Comprehensive
Epilepsy Center.

A version of this op-ed appears in print on February 13, 2014, on page
A27 of the New York edition with the headline: We Need Proof on Marijuana.
_______________________________________________
Dd-world mailing list
https://lists.tni.org/mailman/listinfo/dd-world

The Local
January 30, 2014

'First ever' bill proposes legal cannabis in France

France is no Amsterdam when it comes to marijuana laws, in fact it has some of the toughest possession statutes in Europe, but a first of its kind bill proposed this week could change that. The lawmaker behind the legislation tells The Local why marijuana should be legalized in France.

People smoking a joint in France face a maximum penalty of a year behind bars and a €3,750 fine for the first offence, yet 13.4 million French people admit to sparking up at least once in their life. Even France's top cop, Interior Minister Manuel Vallls, said in a recent interview, he'd tried it "maybe once."

The numbers go up as you look at the younger portion of the population.
France had the unhappy distinction of being the European "champion" of teen pot smokers in 2011 when 24 percent of its 16-year-old kids admitted to smoking at least once a month, daily Le Monde reported.

Not surprisingly legalizing cannabis has come up regularly in France, but the discussion never has never gotten far. In fact, it was only this month that authorities announced medical cannabis spray Sativex had been authorized for sale in France, though only by prescription and solely to multiple sclerosis patients.

It stands in marked contrast to France's more liberal neighbour to the north, the Netherlands, which decriminalized personal use of pot nearly
40 years ago. American states Colorado and Washington went a step further when their voters fully legalized personal possession and use of marijuana in 2013.

Is it France's turn next? French Senator Esther Benbassa, a green party member who represents an area on the south east border of Paris, believes it's time to change. She also claims the legalization law she proposed on Tuesday is the first of its kind in France.

Her law would allow government-run retail stores to sell marijuana to adults for recreational use, though the full details won't be available until the law is unveiled to the press on February 6th. Benbassa told The Local why she is pushing for legalization.

"It's a subject that remains taboo in France. We have the impression that if we legalize cannabis, all the children, everyone, is going to start taking it. We are among the countries with the most restrictive laws in Europe, but at the same time the number of cannabis smokers continues to increase. There is really a paradox.

"The fact that we proposed the law now is related to what's happening in the United States, but we were working on it before. If the law has changed in Washington and Colorado, we felt we had to open the debate now. Prohibition is useless.

"And American President Barack Obama's statement that marijuana is not any more dangerous than alcohol, that also made us realize it's time.

"It makes more sense to legalize cannabis in order to better control it.
For example, the growing and distribution of cannabis, but why not also check the quality? Why not do more drug abuse prevention? Why not shelter children from drug dealers that sell in front of schools?

"It would help in the fight against the mafia and drug dealers. Why not invest the money that the government would make from legalizing and taxing cannabis into drug abuse prevention?

"We believe that today it is an established fact that people smoke cannabis. So let's be responsible.

"Compared to the Netherlands, we very far behind. In France we are very repressive when it comes to drugs, but with other things as well. Our politicians make rules based on the question of security.

"I was on a radio show and was asked by professor of medicine if I was going to distribute hash in schools. There are people out there who will try to misguide people and say 'these leftists are trying to destroy France.' They say we want all the kids to smoke cannabis and make society more indulgent. It's not true.

"The United States is conservative as well, but it's pragmatic. But in France we are conservative without willing to be practical."

As for whether she has ever smoked marijauana, Benbassa asserted the eroding French tradition of keeping quiet about the private lives of public figures.

"That's a private matter and I'm not going to talk about it."

Joshua Melvin (joshua.melvin@thelocal.com) _______________________________________________
Dd-world mailing list
https://lists.tni.org/mailman/listinfo/dd-world

 

 

 

CBC’s Day 6 - Host Brent Bambury gives listeners the tools they need to make brilliant dinner party conversation! This populist weekly magazine show blends the best of the worlds of news, current affairs, pop culture, the net, lifestyle and leisure. Playful and relevant! Day 6 gives listeners a fresh perspective on the week.

 

Episode 168, Feb. 8, 2014: Psychedelics' Therapeutic Potential, Busting the TSA, Grandfather of the Snowboard and more

 

http://podcast.cbc.ca/mp3/podcasts/day6_20140207_96967.mp3

 

 

 

 

 

 

 

Medical marijuana perception changes Global News February 13, 2014

 

 

 

 

Vancouver clinic wants federal approval to provide drug-injection services By Wendy Stueck Globe and Mail February 13, 2014

 

 

 

Psychedelic drugs: harmful or therapeutic? Aljazeera.com Have we lost decades of research on mental health disease because of legal controls on psychedelic drugs? Some scientists claim LSD and MDMA ... Flag as irrelevant

 

 

 

 

.

VPD won't crack down on vending machines Two vending machines installed in DTES to sell crack cocaine pipes By Mike Howell Vancouver Courier February 11, 2014

 

 

 

 

Ottawa's harm reduction efforts complex, could include supervised injection sites By Sarah Anderson 580 CFRA February 10, 2014

 

 

See attached

 

 

 

 

Vancouver home to Canada's first crackpipe vending machines CTV News February 8, 2014

 

 

 

Subject: From the Guardian: Nick Clegg: Britain must join debate on new approach to war on drugs

Deputy PM angry at Tory refusal to debate alternatives and says: 'If you are anti-drugs, you should be pro-reform'

Jamie Doward

Saturday 8 February 2014

The Observer

http://www.theguardian.com/politics/2014/feb/08/clegg-britain-must-join-drugs-debate

----

Nick Clegg has dragged the case for reforming the drugs laws to the centre ground of British politics, saying that blanket prohibition has seen cocaine use triple in less than 20 years, a trend that has helped perpetuate conflict and violence in South America.

Writing in today's Observer, after a week in which he visited Colombia to learn first-hand the devastating effects that Europe's enthusiasm for cocaine has had on the country, Clegg said the UK needed to be at the heart of the debate about potential alternatives to blanket prohibition and that he wanted to see an end to "the tradition where politicians only talk about drugs reform when they have left office because they fear the political consequences".

The deputy prime minister said such an approach "has stifled debate and inhibited a proper examination of our approach. Put simply, if you are anti-drugs, you should be pro-reform".

His comments will be seen by some observers as politically expedient, designed to distance the Lib Dems from the Tories in the runup to the next election. In his article, Clegg expresses his frustration "at my coalition partner's refusal to engage in a proper discussion about the drugs problem".

In some of the most outspoken comments on the issue by a serving British politician, Clegg laments the current situation in which "one in five young people have admitted taking drugs in the last year", and "cocaine use has more than trebled since 1996" and claims that "every time someone dies of an overdose it should shame our political class".

Looking to 2016, when the UN is due to hold a meeting to discuss potential reform of its prohibitionist drug conventions, Clegg states: "The UN drug conventions badly need revising. I want European countries to work together to agree a common position in favour of reform to take to that discussion in 2016. The UK can lead the debate in Europe and Europe can lead the debate in the world. But we must be prepared to start afresh with a new mindset and be prepared to do things differently."

His intervention comes as a growing number of US states move towards a regulated trade in marijuana, and at a time when increasing numbers of Latin American countries have stated that the war on drugs doesn't work and are demanding that the world consider alternative approaches.

During his visit, Clegg met the country's president, Juan Manuel Santos, as well as former paramilitaries, guerrillas and human rights representatives. "All were clear about the central role of the drugs trade in perpetuating conflict and violence and the need to build a better future," Clegg says. "Many people in Britain and the rest of Europe will be unaware of the impact drug use in western nations has on countries on the frontline of the drugs trade."

Reiterating his call for a royal commission on Britain's drugs laws, Clegg says future legislation should be based on "what works, not guesswork". The Lib Dems are conducting a review of international alternatives which will produce what Clegg claims is "the first proper UK government report examining different approaches in other countries".

It is clear the deputy prime minister believes there is a need for politicians of all parties to confront an issue in a non-partisan way if the harm caused by drugs is ever to be tackled successfully.

"If Britain were fighting a war where 2,000 people died every year, where increasing numbers of our young people were recruited by the enemy and our opponents were always a step ahead, there would be outcry and loud calls for change," Clegg says. "Yet this is exactly the situation with the so-called "war on drugs" and for far too long we have resisted a proper debate about the need for a different strategy."

His comments, which will dismay those who believe change will encourage drug taking, were warmly received by pro-reform campaigners.

"Bad drug policies have an international impact, whether it's black market related violence or borderless health crises," said Kasia Malinowska-Sempruch, director of the Open Society Global Drug Policy Foundation. "So charting a new course is the job of every country. A number of European countries developed great health services for people who use drugs but far less attention has been paid to the issues faced by producer and transit countries."

If you have any questions about this email, please contact the theguardian.com user help desk: userhelp@theguardian.com.

theguardian.com Copyright (c) Guardian News and Media Limited. 2014 Registered in England and Wales No. 908396 Registered office: PO Box 68164, Kings Place, 90 York Way, London N1P 2AP

http://www.medicaldaily.com/open-science-or-protective-laws-ending-restrictions-psychoactive-drug-research-268849

Medical Daily Open Science Or Protective Laws? Ending Restrictions On Psychoactive Drug Research Medical Daily LSD, MDMA (ecstasy), psilocybin (magic mushrooms), and marijuana are all classified under the Controlled Substances Act of 1970 as Schedule 1 ...

 

 

RT

 

Researchers Conduct First Successful LSD-Assisted Therapy in Nearly 50 Years

http://firsttoknow.com/successful-lsd-assisted-therapy/

by Elysia McMahan

For the first time in nearly 50 years, researchers are being allowed to study the medical properties of one of the most tightly controlled substances ever created: lysergic acid diethylamide or LSD.

Despite generating some promising results with psychedelics in treating psychiatric conditions, alcoholism, and modeling mental illness, in 1968 the government classified LSD as a Schedule I substance. This meant that even for research, control of this mind-altering substance had been significantly tightened.

It’s only now, as a new generation of scientists are beginning to return to the thought that it can be used as medicine, that the world is finally turning their backs on the stigma (when rumors spread about a person jumping out of a 4th story window while under the influence of LSD, there was mass hysteria surrounding the possible psychotic dangers of the drug ) that has troubled psychedelic science in the past. As more limitations are lifted from the range of scientific research, innovations in fields such as holistic health, psychotherapy, and medicine will continue to emerge.

A recently completed Swiss study found that two LSD-assisted psychotherapy sessions had successfully diminished anxiety in end-of-life patients.

According to the study, which was the first “double-blind, placebo-controlled investigation of LSD-assisted psychotherapy since the early 1970s,” 11 of the 12 subjects had not previously done LSD and there any serious unpleasant or harmful effects of the drug, even in people facing death.

The study was conducted by Peter Gasser, M.D., who wrote a  letter to friends and colleagues at its conclusion. In his letter, he writes that “all the 12 participants reported a benefit from the treatment.”

He goes on to say:

I am proud to say that we had in 30 sessions (22 with full dose 200 μg LSD and 8 with placebo dose 20 μg LSD) no severe side effects such as psychotic experiences or suicidal crisis or flashbacks or severe anxieties (bad trips)…That means that we can show that LSD treatment can be safe when it is done in a carefully controlled clinical setting.

The paper was accepted for publication in the peer-reviewedJournal of Nervous and Mental Disease in December. You can read the full results of the monumental study in this clinical report.

This promising study should continue to pave the way for research regarding therapeutic applications as well as psychological and scientific implications of LSD.

It is clear that psychedelics may offer a resolution to countless traumas or ailments suffered by the general population. Perhaps it may even lead the way for people to expand their consciousness and gain a deeper understanding of themselves, the planet, and their connection with everyone around them.

MAPS founder Rick Doblin pointed out in a 2012 interview that ”psychedelics are off-patent, can’t be monopolized, and compete with other psychiatric medications that people take daily.”

According to the DEA, it takes about nine months to get FDA and DEA approval for a license to research Schedule I substances such as LSD, though researchers are a little more skeptical. It appears that the main issue with studying these psychedelics for medical use is simply that no pharmaceutical company wants (or needs) to get involved since there is no money in it for them.

Interested in supporting this kind of research? Consider donating to MAPS.

 

 

 

 

 

 

---

http://psypressuk.com/2014/02/07/interview-with-manifesting-minds-editor-brad-burge-of-maps/

Interview with Manifesting Minds editor Brad Burge of MAPS
Posted by PsypressUK ⋅ February 7, 2014        ⋅ Leave a Comment
Filed Under  drugs, interview, mdma, psychedelics, PTSD, therapy        


The following interview is with Brad Burge, Director of Communications
and Marketing at the Multidisciplinary Association of Psychedelic
Studies (MAPS), and co-editor of the Manifesting Minds anthology (2014).

Manifesting Minds is a collection of articles previously published in
the MAPS Bulletin, which since its launch has been an important source
of information on psychedelic research. In many respects, this
publication feels like a testament to the bulletin's longevity and
willingness to embrace different aspects of psychedelics.

[PsypressUK]
Can you tell us a little about the special editions, from which these
articles have been taken, and how they first came about?

[Brad]
Though our primary focus is scientific research, educating the public is
also an essential part of our mission and the MAPS Bulletin has been a
way to do that.

In the early days of psychedelic research, it seemed to be important and
necessary to invest in creating a publication that people could be proud
to leave on their coffee table and share with others, a credible and
professional source that would encourage people to have open, honest
conversations about psychedelics.

Early Bulletins focused on providing updates on our various research and
education projects, until we released the first special edition in
autumn of 2000, themed: "Creativity." It was a success, we published
additional special editions including "Sex, Spirit, and Psychedelics";
"Rites of Passage: Kids and Psychedelics"; "Technology and
Psychedelics"; "Psychedelics and Ecology"; "Psychedelics, Death, and
Dying"; "Psychedelics and the Mind-Body Connection"; and "Psychedelics
and the Popular Arts". Our most recent special edition was on
"Psychedelics, Psychiatry, and Psychology," and the next one in Spring
2014 will be "Psychedelics and Education."

[PsypressUK]
The publication of Manifesting Minds comes at a time when psychedelic
research in general appears to be on an up-swing, yet many of the areas
on which it touches are still understood to be fringe ideas. In the
future, what fields and disciplines other than the psychiatric do you
think headway will be made with? And why?

[Brad]
Psychedelics have been (and continue to be) used for spiritual and
religious purposes in various locations around the world, notably the
União do Vegetal (Brazil) which uses ayahuasca, the Native American
Church (USA) which uses peyote, and the Bwiti people (South Africa) who
use iboga or ibogaine, just to name a few. These compounds are integral
parts of ceremonies and rites of passage and when used in these
culturally supported contexts, users often have strong spiritual
experiences, or experiences that help them heal from mental or physical
illness, or experiences that enhance their creativity or their
connection to the natural world. We hope to open up legitimate fields of
scientific inquiry into all of these areas.

As research into the medical applications of psychedelics moves forward,
these long-established traditional uses are also seeing an upswing in
interest as Westerners seek spiritual purpose, greater understandings of
altered states of consciousness, and new modes of healing.

There is also increasing interest in using psychedelics to enhance
creative thinking, not just among artists, but also among scientific
communities, the technology sector, and computer programmers as a way to
approach problem solving. The most notable testament to this application
is Steve Jobs, who at one point linked his early LSD experiences to
advancements in the development of Apple. After his death, the overlap
between LSD and computer programming gained widespread media attention.

[PsypressUK]
One of the highly focused areas of psychedelic research at the moment is
with post-traumatic stress disorder (PTSD). Can you tell us what work
MAPS has and is currently helping to undertake in this area?

[Brad]
MAPS is conducting Phase 2 clinical trials with the specific intent to
develop MDMA into a prescription drug, to be used in conjunction with
therapy, in a clinic, as a treatment for PTSD. We have study sites
around the world including Vancouver, Charleston, Boulder, and Tel-Aviv.
Phase 2 research is an opportunity to test and adjust our protocol so
that the results can be duplicated in many more subjects during Phase 3,
which we hope to begin two years from now. So far, our results are
promising, showing that MDMA-assisted psychotherapy may be a more
effective PTSD treatment than leading pharmaceuticals, even among
patients who are treatment-resistant. Our long-term follow-up study
showed that results were sustained for over three years. There is a
strong possibility that MDMA-assisted psychotherapy will be legally
available by around 2022.

[PsypressUK]
The treatment of US soldiers with PTSD has been a bone of contention in
some quarters, so far as it seemingly picks a side, and ignores the
effects on innocent civilians. Why do you think the focus has not been
on the total negative mental health effects of war situations? And what
can be done to improve this situation?

[Brad]
Our current largest study of MDMA-assisted psychotherapy for PTSD is
focused on U.S. veterans as well as police officers, fire fighters, and
police officers with service-related PTSD. Our first complete pilot
study, with an 83% success rate, was primarily in female survivors of
sexual assault and abuse. It's a huge exaggeration to say that we've
only—or even primarily—been focused on veterans when our research is
helping people with PTSD from many causes.

One of the facts of war is that the wounds of the victors are easier to
treat than the wounds of the defeated. U.S. veterans returning from
combat are the victors in the sense that they get to return home to a
safe place. Their minds and bodies may be in pieces, but at home they
have a chance to rest and to explore different treatments. We just can't
access some of the global populations most in need of psychedelic
treatments, as evidenced by the Jordanian FDA's refusal to let us start
research in that country.

We believe that military personnel and civilians are equally deserving
of the best possible care we can give them. Helping a soldier
reintegrate into a normal life, stop having nightmares and flashbacks,
and giving them a chance to lead a healthy and happy life are not the
same as supporting the wars in which they fought.

The best we can do now to expand access to these treatments for
everyone—not just for military personnel but for those suffering from
PTSD as a result of war, terrorism, sexual assault, violent crime,
natural disasters, childhood trauma, or any other cause—is to increase
the amount of mainstream support we receive from the media,
policymakers, and the public at large. If government agencies can
embrace MDMA-assisted psychotherapy for PTSD research, we'll have opened
a door for psychedelic treatments for everyone who can benefit from them.

[PsypressUK]
Thank you for answering our questions, Brad. Best of luck with the
anthology!
-----------------
MAPS_Forum@maps.org, a member service of the Multidisciplinary Association for Psychedelic Studies (see www.maps.org/donate ). To subscribe, email maps_forum-subscribe@maps.org . To unsubscribe, email maps_forum-unsubscribe@maps.org .

http://www.maps.org/mailman/listinfo/maps_forum